|
Found 39 result(s) FROM 1963 pages containing the term 'autoantibodies'.
Wednesday Aug 19, 2009
Echo Urged to Rule Out PAH in High-Risk Lupus
Echocardiogram screening may be useful in identifying pulmonary arterial hypertension in high risk lupus patients...
Monday Apr 27, 2009
Two Big Steps for Lupus Nephritis Research
Genes that encode CXCR4/CXCL12 and kallikrein help determine whether lupus patients will develop kidney damage...
Thursday Jan 22, 2009
Rheumatoid Arthritis Hits Women Harder
Women are more likely than men to suffer from rheumatoid arthritis, and experience the disease more severely...
Friday Dec 05, 2008
SSc Risk 60-Fold Higher in Raynaud's with SSc Antibodies, NCM Changes
Microvascular damage and systemic sclerosis (SSc)-specific antibodies can predict which Raynaud's phenomenon patients will progress to systemic sclerosis, and when...
Monday Nov 05, 2007
Lab-on-a-Chip Promises Fast Profile of RA Patients' Autoantibodies
A new technique promises fast, inexpensive serum antibody profiling in RA patients without the need for fluorescent labeling or preprocessing...
Wednesday Oct 31, 2007
Coley Initiates Phase I Study of First-in-Class TLR Antagonist, CPG 52364, for the Treatment of Systemic Lupus Erythematosus
Coley Pharmaceutical Group, Inc, an international biopharmaceutical company having a pipeline of Toll-Like Receptor (TLR) therapeutic product candidates, announced that it has dosed its first subject in a phase I study of its novel, orally-available TLR Therapeutic drug candidate for the treatment of systemic lupus erythematosus (SLE)...
Friday Oct 26, 2007
Rituximab May "Reboot" Immune System in Some Lupus Patients
A subgroup of systemic lupus erythematosus (SLE) patients treated with rituximab to deplete B-cells have delayed recovery of memory B-cells in addition to a prolonged response, suggesting that treatment helps "reboot" the immune system...
Thursday Sep 20, 2007
Researchers Identify Additional RA, SLE Genes
Genetics researchers report a new variant on chromosome 9 associated with anti-CCP-positive RA and a mutation of STAT4 on chromosome 2q associated with both RA and lupus...
Friday Sep 14, 2007
Autoantibodies Associated With Lupus Can Be Removed by Plasmapheresis
Antibodies against the VRT101 laminin epitope correlate with SLE disease activity and can be removed by extracorporeal immunoadsorption...Amital H, et al. Rheumatology. 2007; doi:10.1093/rheumatology/kem181 [Epub ahead of print].
Tuesday Aug 07, 2007
Medarex Announces Initiation by Licensing Partner Novartis of Phase III Clinical Trial for Muckle-Wells Syndrome, a Rare Inherited Autoinflammatory Disease
Medarex, Inc announced that Novartis Pharmaceuticals AG has advanced ACZ885, a fully human monoclonal antibody targeting interleukin-1β (IL-1 β), to a phase III clinical trial for Muckle-Wells syndrome (MWS), an inherited systemic autoinflammatory disease...
Thursday Jul 19, 2007
ACR REF Campaign Taps Brightest Minds to Cure RA
The American College of Rheumatology Research and Education Foundation has awarded $6 million in grant money to 15 arthritis researchers as part of a new "Within Our Reach: Finding a Cure for Rheumatoid Arthritis" campaign.
Friday Jun 15, 2007
Has the Increasing Use of Anti-TNF Drugs Led to a Rise in Cases of Drug-Induced Lupus? Study Says Yes
The increasing use of TNFα inhibitors to treat rheumatic, digestive, and cutaneous diseases has led to a corresponding rise in the number of cases of drug-induced lupus...
Thursday Jun 14, 2007
More Patients Needed to Validate Biomarkers and Genotyping in Rheumatoid Diseases
Biomarkers and genotyping technology have outpaced the number of patient cohorts available for validation studies in rheumatoid diseases, but the new approaches are expected to change how clinicians assess disease susceptibility and predict response to therapy...
Friday Jun 01, 2007
HGS and GSK Initiate Second Phase III Clinical Trial of LymphoStat-BR (Belimumab) in Lupus
Human Genome Sciences, Inc. announced that dosing has begun in BLISS-52, the second of two pivotal phase III clinical trials of LymphoStat-B® (belimumab), a human monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS®), in patients with active systemic lupus erythematosus (SLE).
Wednesday May 23, 2007
New SLE Treatments Hit B-Cells From Several Directions
Various new treatments directed at B-cells offer mounting interest in SLE arsenal...
Friday May 11, 2007
Lupus Gene Protects Against Malaria, But Does Malaria Also
Prevent Lupus?
A mutation that renders the FcγRIIb receptor
nonfunctional vastly improves monocytes' ability to clear malaria parasites,
protects lupus-prone mice against malarial disease, and may explain the high
prevalence of lupus in some population groups. Interestingly, there is also
some evidence suggesting that the body's response to malarial infection might
reduce lupus severity in some situations...Clatworthy MR, et al. Proc Natl
Acad Sci USA.
2007;104:7169-7174.
Wednesday Apr 18, 2007
Death Forces Early Termination of Study of Infliximab in Systemic Vasculitis
Adverse events, including one death among nine patients treated, forced early termination of infliximab trial in systemic vasculitis...
Friday Apr 06, 2007
Shared Epitope Either Raises or Lowers Risk of RA-Related Antibodies, Depending on Neighboring Amino Acids
HLA-DRB1 shared epitope alleles can either predispose to or protect against production of autoantibodies associated with early, erosive RA, depending on which amino acids occupy neighboring positions...
Monday Feb 26, 2007
Lupus Patients Clear UV-Damaged "Sunburn Cells" but May Have Unusual Inflammatory Reaction to Them
Sunlight can trigger new skin lesions and worsen disease activity in lupus; this might reflect an abnormal inflammatory response to UV-damaged cells, despite the ability to clear them normally from the epidermis...
Thursday Feb 15, 2007
HGS and GSK Initiate Phase III Clinical Trial of LymphoStat-B® in Lupus
Human Genome Sciences, Inc and GlaxoSmithKline PLC announced the initiation of dosing in BLISS-76, one of two pivotal phase III clinical trials of LymphoStat-B® (belimumab, a human monoclonal antibody that blocks the biological activity of B-lymphocyte stimulator, or BLyS®) in patients with active systemic lupus erythematosus (SLE)...
Friday Dec 22, 2006
New Studies Suggest That Autoantibodies Damage Brain, Cause Cognitive Impairment in SLE Patients
The cognition and mood disturbances common in lupus patients might be due in part to autoantibodies that target the NMDA receptor and cause progressive damage of the amygdala and hippocampus...
Monday Nov 27, 2006
Rituximab in RA
Rituximab prevents joint damage, can be given repeatedly, and does not block response to influenza vaccine in RA patients... Presented at ACR 2006 Meeting.
Monday Nov 13, 2006
Biomarkers Might Be Modifiable Risk Factors for RA
Autoantibodies may lead to risk reduction strategies for preventing RA... Holers VM. Presented at ACR 2006 Meeting.
Monday Nov 13, 2006
Beyond HLA: Genetic Studies Find Markers Associated With Elevated Risk for RA
HLA DR4 is only one of the genetic factors involved in RA, and new genomics techniques are beginning to fill in the rest of the picture... Gregersen PK. Presented at ACR 2006 Meeting.
Friday Jul 14, 2006
Researchers Map the Genetic Substrate of RA
Two new reports on genetics and RA show that a mutation in the PTPN22 gene not only increases RA susceptibility but hastens disease progression and that development of RA is associated with altered expression of disease-associated genes, apparently in response to environmental or other nongenetic factors. Lie B, et al. EULAR 2006; Haas CS, et al. Arthritis Rheum. 2006;54:2047-2060.
Monday May 08, 2006
Additional Neuropathies Linked to TNF Inhibitors
Guillain-Barré syndrome, demyelinating and axonal neuropathies, and a central nervous system syndrome have been reported recently in patients treated with TNF inhibitors... Shin I-SJ, et al. Arthritis Rheum. 2006;54:1429-1434; Jarand J, et al. J Rheumatol. 2006;33:1018-1020.
Tuesday Apr 18, 2006
Studies Suggest Link Between Smoking and Autoantibody Production
Two new studies have established an association between smoking and the development of autoantibodies and suggest that rheumatologists should include smoking cessation efforts as part of a comprehensive care plan for patients with autoimmune diseases... Freemer MM, et al. Ann Rheum Dis. 2006;65:581-584.
Wednesday Feb 01, 2006
Stem Cell Transplantation Shows Promise in Treatment-Resistant Lupus
Autologous nonmyeloablative hematopoietic stem cell transplantation ameliorates disease activity, improves serologic markers, and stabilizes or reverses organ dysfunction in about half of patients with treatment-refractory systemic lupus erythematosus... Burt RK, et al. JAMA. 2006;295:527-535.
Friday Nov 04, 2005
Study Provides Additional Clues to the Causes of Systemic Sclerosis and the Potential Efficacy of Paclitaxel
New research in a murine model points to the ability of low-dose paclitaxel (Taxol®) to modulate transforming growth factor-beta (TGF-ß) and lessen fibrosis in systemic sclerosis patients, findings that also provide additional clues to the pathogenesis of the disease... Liu X, et al. PloS Med. 2005;2:e354
Friday Oct 07, 2005
Marked Decrease in Pregnancy Loss Seen in Women with Lupus
Largely due to improvements in perinatal monitoring and disease management, there has been a significant decrease in pregnancy loss among women with systemic lupus erythematosus over the past 40 years . . . Clark CA, et al. J Rheumatol. 2005;32:1709-1712.
Thursday Oct 06, 2005
Human Genome Sciences' LymphoStat-Bâ„¢ for Lupus Fails to Meet Primary Endpoints in Phase II Trial
Human Genome Sciences, Inc (Rockville, Md), announced that its investigational drug for lupus, LymphoStat-Bâ„¢, (belimumab) failed to meet the overall primary efficacy endpoints...
Sunday Aug 14, 2005
Whatman/Schleicher & Schuell and the Private Institute for Immunology and Molecular Genetics to Market Protein Chip–Based Autoimmune Assay
Whatman/Schleicher & Schuell and the Private Institute for Immunology and Molecular Genetics of Germany...
Monday Jun 13, 2005
IL-6 Blocker Shows Promise in Systemic Onset Juvenile Idiopathic Arthritis
More evidence emerging on the therapeutic potential of the experimental IL-6 blocker tocilizumab in the management of severe SJIA... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Tuesday Mar 22, 2005
IL-6 Blocker "Promising" in Systemic Onset Juvenile Idiopathic Arthritis
Small study demonstrating efficacy and safety of MRA in juvenile arthritis, combined with promising results in treatment of other conditions, suggests that IL-6 inhibitors may play an important role in controlling inflammatory disease...Yokota S, et al. Arthritis Rheum. 2005;52:818-825.
Wednesday Feb 23, 2005
New Findings Confirm Predictive Power of Cyclic Citrullinated Peptide Antibodies in Patients With Very Early Rheumatoid Arthritis
Study offers further evidence that the presence of antibodies to CCP in addition to RF in patients with early inflammatory arthropathy can forecast the development of RA... Raza K, et al. J Rheumatol. 2005;32:231-238.
Tuesday Dec 21, 2004
SLE Patients Treated with TNF-ÃŽalpha Blockade Show Improvement
Study indicates that TNF-alpha blocker may reduce SLE disease activity in patients' joints and kidneys, without serious adverse events; need for larger clinical trials cited... Aringer M, et al. Arthritis Rheum. 2004;50: 3161-3169.
Monday Nov 15, 2004
New Approaches Show Promise in Refining Treatment and Assessment of SLE
Autologous stem cell transplant and rituximab show promise in refractory disease, and the erythrocyte sedimentation rate test may be more useful than CRP in showing disease activity... Alexander T et al. Presented at: Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Tex.
Thursday Sep 02, 2004
B Lymphocyte Depletion Seen with Rituximab in Seropositive RA Patients
A treatment often used in B-cell non-Hodkin's lymphoma may have promise for methotrexate-refractory RA patients.
Friday Aug 27, 2004
Elevated CRP Before Onset of RA
Patients with RA have elevated CRP levels several years before the onset of symptoms, as seen in blood samples drawn when they were blood donors. (Nielen MM, et al. Arthritis Rheum. 2004;50:2423-2427.)
|
